Enzymatic kinetic studies with the non-nucleoside HIV reverse transcriptase inhibitor U-9843

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• Human Immunodeficiency Virus type 1 (HIV-1) reverse transcriptase (RT) is a critical enzyme for viral replication.
• Developing potent and specific inhibitors of HIV-1 RT is a key strategy for antiviral therapy.
• The polymer of ethylenesulfonic acid (U-9843) has been identified as a potential inhibitor.

Purpose of the Study:

• To investigate the inhibitory potential of the polymer of ethylenesulfonic acid (U-9843) against HIV-1 RT.
• To elucidate the mechanism of inhibition of HIV-1 RT by U-9843.
• To assess the antiviral activity and toxicity of U-9843 in HIV-infected cells.

Main Methods:

• Enzymatic kinetic studies using synthetic template:primers to analyze HIV-1 RT polymerase activity.
• Testing inhibition of RTs from other retroviruses like Avian Myeloblastosis Virus (AMV) and Moloney Murine Leukemia Virus (MLV).
• Evaluating antiviral activity and cytotoxicity in HIV-infected lymphocytes in tissue culture.

Main Results:

• U-9843 demonstrated potent inhibition of HIV-1 RT and RTs from AMV and MLV.
• Kinetic studies indicated noncompetitive inhibition with respect to template:primer binding and dNTP binding sites, suggesting interaction with a distinct site.
• The drug also impaired DNA-dependent DNA polymerase activity and RNase H function of HIV-1 RT.

Conclusions:

• U-9843 is a potent inhibitor of HIV-1 RT with broad-spectrum activity against other retroviral RTs.
• The mechanism of inhibition involves interaction with a site crucial for all three key functions of HIV-1 RT: RNA-directed DNA polymerase, DNA-directed DNA polymerase, and RNase H.
• U-9843 exhibits excellent antiviral activity at nontoxic doses, highlighting its potential as an anti-HIV therapeutic agent.